肿瘤药学Issue(5)：379-382,4.DOI:10.3969/j.issn.2095-1264.2014.078
调强放疗联合多西他赛单药同期化疗对老年局部晚期非小细胞肺癌的疗效分析
Efficacy of IMRT Combined with Docetaxel Concurrent Chemotherapy for Elderly Patients with Local Advanced Non-small Cell Lung Cancer
蓝玉宏 1江晓聪 1谢福川 1白力2
作者信息
- 1. 惠州中心人民医院肿瘤放射治疗中心，广东 惠州，516001
- 2. 广州医科大学附属肿瘤医院放疗科，510095，广东 广州
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy of intensity modulation radiotherapy (IMRT) combined with docetaxel concurrent chemotherapy in the treatment of local advanced non-small cell lung cancer (LA-NSCLC) in elderly patients. Methods In this study, 79 elderly patients who were firstly diagnosed with LA-NSCLC were randomly divided into experimental group (40 cases) and control group (39 cases). The experimental group was treated by IMRT combined with concurrent docetaxel chemotherapy (70 mg·m-2, every three weeks) for two cycles, while the control group was only treated by IMRT. By the end of IMRT treatment, all patients were treated with two more cycles of docetaxel monotherapy. After treatment, the clinical efficiency, 2-year survival rate and toxic reactions were observed and compared. Results The response rate of the experimental group was significantly higher than that of control group (77.5%vs. 61.5%, P=0.036). The 2-year survival rate and disease control rate of the treatment group were signifi-cantly higher than those of control group, which were 22.5%vs. 12.8%, P=0.029;and 52.5%vs. 35.9%, P=0.013. The incidence of radiation pneumonitis and the bone marrow suppression response rate in the treatment group were higher than in the control group, but did not affect the results. Conclusion The IMRT combined with docetaxel concurrent chemotherapy showed better clinical effi-cacy than IMRT alone in the treatment of elderly LA-NSCLC patients. Its safety is acceptable and it is worth of being widely applied.关键词
调强放疗/多西他赛/非小细胞肺癌/同期化疗Key words
IMRT/Docetaxel/NSCLC/Concurrent chemotherapy分类
医药卫生引用本文复制引用
蓝玉宏,江晓聪,谢福川,白力..调强放疗联合多西他赛单药同期化疗对老年局部晚期非小细胞肺癌的疗效分析[J].肿瘤药学,2014,(5):379-382,4.
